nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—FGFR2—uterine cancer	0.422	1	CbGaD
Pazopanib—UGT1A1—Etoposide—uterine cancer	0.0274	0.114	CbGbCtD
Pazopanib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0271	0.113	CbGbCtD
Pazopanib—ABCG2—Dactinomycin—uterine cancer	0.0267	0.111	CbGbCtD
Pazopanib—ABCG2—Carboplatin—uterine cancer	0.0179	0.0747	CbGbCtD
Pazopanib—CYP2C8—Progesterone—uterine cancer	0.0179	0.0747	CbGbCtD
Pazopanib—ABCG2—Etoposide—uterine cancer	0.0151	0.0628	CbGbCtD
Pazopanib—CYP1A2—Progesterone—uterine cancer	0.0139	0.0578	CbGbCtD
Pazopanib—ABCB1—Progesterone—uterine cancer	0.0121	0.0506	CbGbCtD
Pazopanib—CYP2D6—Progesterone—uterine cancer	0.0114	0.0476	CbGbCtD
Pazopanib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.011	0.0457	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—uterine cancer	0.0103	0.0428	CbGbCtD
Pazopanib—ABCB1—Dactinomycin—uterine cancer	0.00962	0.0401	CbGbCtD
Pazopanib—CYP2C8—Etoposide—uterine cancer	0.00802	0.0334	CbGbCtD
Pazopanib—CYP3A4—Progesterone—uterine cancer	0.00727	0.0303	CbGbCtD
Pazopanib—CYP1A2—Etoposide—uterine cancer	0.00621	0.0259	CbGbCtD
Pazopanib—ABCB1—Etoposide—uterine cancer	0.00543	0.0226	CbGbCtD
Pazopanib—ABCB1—Doxorubicin—uterine cancer	0.0037	0.0154	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—uterine cancer	0.00349	0.0145	CbGbCtD
Pazopanib—CYP3A4—Etoposide—uterine cancer	0.00325	0.0136	CbGbCtD
Pazopanib—CYP3A4—Doxorubicin—uterine cancer	0.00222	0.00925	CbGbCtD
Pazopanib—PLK4—Teniposide—Etoposide—uterine cancer	0.000752	0.332	CbGdCrCtD
Pazopanib—FGFR1—myometrium—uterine cancer	0.000598	0.00587	CbGeAlD
Pazopanib—RIOK2—decidua—uterine cancer	0.000576	0.00566	CbGeAlD
Pazopanib—TAOK1—female reproductive system—uterine cancer	0.000574	0.00564	CbGeAlD
Pazopanib—ITK—vagina—uterine cancer	0.000571	0.00561	CbGeAlD
Pazopanib—FGFR3—renal system—uterine cancer	0.000565	0.00555	CbGeAlD
Pazopanib—RIOK2—endometrium—uterine cancer	0.000546	0.00537	CbGeAlD
Pazopanib—STK36—uterine cervix—uterine cancer	0.000543	0.00533	CbGeAlD
Pazopanib—PI4KB—uterine cervix—uterine cancer	0.000534	0.00525	CbGeAlD
Pazopanib—AURKC—female reproductive system—uterine cancer	0.000532	0.00523	CbGeAlD
Pazopanib—RIOK2—mammalian vulva—uterine cancer	0.000529	0.00519	CbGeAlD
Pazopanib—FGFR3—mammalian vulva—uterine cancer	0.000529	0.00519	CbGeAlD
Pazopanib—LIMK2—uterine cervix—uterine cancer	0.000525	0.00516	CbGeAlD
Pazopanib—TAOK1—female gonad—uterine cancer	0.000523	0.00514	CbGeAlD
Pazopanib—TAOK1—vagina—uterine cancer	0.000519	0.0051	CbGeAlD
Pazopanib—PI4KB—smooth muscle tissue—uterine cancer	0.000519	0.0051	CbGeAlD
Pazopanib—STK36—decidua—uterine cancer	0.000517	0.00508	CbGeAlD
Pazopanib—PI4KB—decidua—uterine cancer	0.000509	0.005	CbGeAlD
Pazopanib—PI4KB—renal system—uterine cancer	0.0005	0.00491	CbGeAlD
Pazopanib—LIMK2—decidua—uterine cancer	0.0005	0.00491	CbGeAlD
Pazopanib—BMPR1B—uterus—uterine cancer	0.000498	0.0049	CbGeAlD
Pazopanib—SH2B3—female gonad—uterine cancer	0.000492	0.00484	CbGeAlD
Pazopanib—STK36—endometrium—uterine cancer	0.000491	0.00482	CbGeAlD
Pazopanib—SH2B3—vagina—uterine cancer	0.000489	0.00481	CbGeAlD
Pazopanib—PLK4—female reproductive system—uterine cancer	0.000487	0.00478	CbGeAlD
Pazopanib—PI4KB—endometrium—uterine cancer	0.000483	0.00475	CbGeAlD
Pazopanib—FLT4—epithelium—uterine cancer	0.000475	0.00467	CbGeAlD
Pazopanib—STK36—mammalian vulva—uterine cancer	0.000475	0.00467	CbGeAlD
Pazopanib—LIMK2—endometrium—uterine cancer	0.000474	0.00466	CbGeAlD
Pazopanib—FLT1—myometrium—uterine cancer	0.000471	0.00463	CbGeAlD
Pazopanib—PIP4K2C—uterine cervix—uterine cancer	0.000469	0.00461	CbGeAlD
Pazopanib—PI4KB—mammalian vulva—uterine cancer	0.000468	0.00459	CbGeAlD
Pazopanib—EPHB6—myometrium—uterine cancer	0.000466	0.00458	CbGeAlD
Pazopanib—FGFR1—uterine cervix—uterine cancer	0.000465	0.00457	CbGeAlD
Pazopanib—STK16—female reproductive system—uterine cancer	0.00046	0.00452	CbGeAlD
Pazopanib—LIMK2—mammalian vulva—uterine cancer	0.000459	0.00451	CbGeAlD
Pazopanib—FGFR3—female reproductive system—uterine cancer	0.000453	0.00445	CbGeAlD
Pazopanib—RIOK2—female reproductive system—uterine cancer	0.000453	0.00445	CbGeAlD
Pazopanib—FLT4—decidua—uterine cancer	0.000449	0.00441	CbGeAlD
Pazopanib—MAP3K19—female reproductive system—uterine cancer	0.000448	0.0044	CbGeAlD
Pazopanib—BMPR1B—female reproductive system—uterine cancer	0.000448	0.0044	CbGeAlD
Pazopanib—MAP3K9—lymph node—uterine cancer	0.000448	0.0044	CbGeAlD
Pazopanib—PIP4K2C—decidua—uterine cancer	0.000447	0.00439	CbGeAlD
Pazopanib—STK10—myometrium—uterine cancer	0.000446	0.00438	CbGeAlD
Pazopanib—PI4KB—uterus—uterine cancer	0.000445	0.00438	CbGeAlD
Pazopanib—MAP3K2—uterine cervix—uterine cancer	0.000444	0.00437	CbGeAlD
Pazopanib—TAOK3—myometrium—uterine cancer	0.000444	0.00436	CbGeAlD
Pazopanib—FGFR1—decidua—uterine cancer	0.000443	0.00435	CbGeAlD
Pazopanib—LIMK2—uterus—uterine cancer	0.000437	0.0043	CbGeAlD
Pazopanib—PIP4K2C—endometrium—uterine cancer	0.000424	0.00417	CbGeAlD
Pazopanib—FGF1—epithelium—uterine cancer	0.000422	0.00415	CbGeAlD
Pazopanib—STK16—female gonad—uterine cancer	0.000418	0.00411	CbGeAlD
Pazopanib—LCK—uterine cervix—uterine cancer	0.000416	0.00409	CbGeAlD
Pazopanib—STK16—vagina—uterine cancer	0.000416	0.00409	CbGeAlD
Pazopanib—RIOK2—female gonad—uterine cancer	0.000412	0.00405	CbGeAlD
Pazopanib—PIP4K2C—mammalian vulva—uterine cancer	0.00041	0.00403	CbGeAlD
Pazopanib—RIOK2—vagina—uterine cancer	0.000409	0.00402	CbGeAlD
Pazopanib—BMPR1B—female gonad—uterine cancer	0.000408	0.00401	CbGeAlD
Pazopanib—FGF1—smooth muscle tissue—uterine cancer	0.000407	0.004	CbGeAlD
Pazopanib—FGFR1—mammalian vulva—uterine cancer	0.000407	0.004	CbGeAlD
Pazopanib—STK36—female reproductive system—uterine cancer	0.000407	0.004	CbGeAlD
Pazopanib—PI4KB—female reproductive system—uterine cancer	0.0004	0.00393	CbGeAlD
Pazopanib—FGFR2—epithelium—uterine cancer	0.000399	0.00392	CbGeAlD
Pazopanib—KDR—myometrium—uterine cancer	0.000398	0.00391	CbGeAlD
Pazopanib—MAP2K5—myometrium—uterine cancer	0.000398	0.00391	CbGeAlD
Pazopanib—LCK—decidua—uterine cancer	0.000397	0.0039	CbGeAlD
Pazopanib—FGFR2—uterine cervix—uterine cancer	0.000395	0.00389	CbGeAlD
Pazopanib—LIMK2—female reproductive system—uterine cancer	0.000393	0.00386	CbGeAlD
Pazopanib—PLK4—Idarubicin—Epirubicin—uterine cancer	0.000392	0.173	CbGdCrCtD
Pazopanib—PLK4—Doxorubicin—Epirubicin—uterine cancer	0.000392	0.173	CbGdCrCtD
Pazopanib—FGF1—renal system—uterine cancer	0.000392	0.00385	CbGeAlD
Pazopanib—CSF1R—myometrium—uterine cancer	0.000389	0.00382	CbGeAlD
Pazopanib—FGFR1—uterus—uterine cancer	0.000388	0.00381	CbGeAlD
Pazopanib—FGFR2—smooth muscle tissue—uterine cancer	0.000384	0.00378	CbGeAlD
Pazopanib—MAP3K2—uterus—uterine cancer	0.00037	0.00364	CbGeAlD
Pazopanib—STK36—female gonad—uterine cancer	0.00037	0.00364	CbGeAlD
Pazopanib—FGFR2—renal system—uterine cancer	0.00037	0.00364	CbGeAlD
Pazopanib—FLT1—epithelium—uterine cancer	0.00037	0.00363	CbGeAlD
Pazopanib—ITK—lymph node—uterine cancer	0.000369	0.00363	CbGeAlD
Pazopanib—STK36—vagina—uterine cancer	0.000368	0.00361	CbGeAlD
Pazopanib—FLT1—uterine cervix—uterine cancer	0.000367	0.0036	CbGeAlD
Pazopanib—PI4KB—female gonad—uterine cancer	0.000364	0.00358	CbGeAlD
Pazopanib—LCK—mammalian vulva—uterine cancer	0.000364	0.00358	CbGeAlD
Pazopanib—PLK4—Idarubicin—Doxorubicin—uterine cancer	0.000363	0.16	CbGdCrCtD
Pazopanib—PLK4—Epirubicin—Doxorubicin—uterine cancer	0.000363	0.16	CbGdCrCtD
Pazopanib—EPHB6—uterine cervix—uterine cancer	0.000362	0.00356	CbGeAlD
Pazopanib—PI4KB—vagina—uterine cancer	0.000362	0.00356	CbGeAlD
Pazopanib—LIMK2—female gonad—uterine cancer	0.000358	0.00351	CbGeAlD
Pazopanib—FLT1—smooth muscle tissue—uterine cancer	0.000356	0.0035	CbGeAlD
Pazopanib—LIMK2—vagina—uterine cancer	0.000355	0.00349	CbGeAlD
Pazopanib—FLT4—female reproductive system—uterine cancer	0.000353	0.00347	CbGeAlD
Pazopanib—KIT—myometrium—uterine cancer	0.000353	0.00347	CbGeAlD
Pazopanib—PIP4K2C—female reproductive system—uterine cancer	0.000351	0.00345	CbGeAlD
Pazopanib—FLT1—decidua—uterine cancer	0.000349	0.00343	CbGeAlD
Pazopanib—STK10—uterine cervix—uterine cancer	0.000347	0.00341	CbGeAlD
Pazopanib—LCK—uterus—uterine cancer	0.000347	0.00341	CbGeAlD
Pazopanib—TAOK3—uterine cervix—uterine cancer	0.000346	0.0034	CbGeAlD
Pazopanib—EPHB6—decidua—uterine cancer	0.000345	0.00339	CbGeAlD
Pazopanib—PDGFRB—myometrium—uterine cancer	0.000345	0.00339	CbGeAlD
Pazopanib—FLT1—renal system—uterine cancer	0.000343	0.00337	CbGeAlD
Pazopanib—TAOK1—lymph node—uterine cancer	0.000336	0.0033	CbGeAlD
Pazopanib—PDGFRA—smooth muscle tissue—uterine cancer	0.000334	0.00328	CbGeAlD
Pazopanib—MAP3K2—female reproductive system—uterine cancer	0.000333	0.00327	CbGeAlD
Pazopanib—FLT1—endometrium—uterine cancer	0.000332	0.00326	CbGeAlD
Pazopanib—STK10—decidua—uterine cancer	0.000331	0.00325	CbGeAlD
Pazopanib—FGFR2—uterus—uterine cancer	0.00033	0.00324	CbGeAlD
Pazopanib—TAOK3—decidua—uterine cancer	0.000329	0.00324	CbGeAlD
Pazopanib—EPHB6—endometrium—uterine cancer	0.000328	0.00322	CbGeAlD
Pazopanib—PDGFRA—decidua—uterine cancer	0.000327	0.00322	CbGeAlD
Pazopanib—STK10—renal system—uterine cancer	0.000325	0.00319	CbGeAlD
Pazopanib—TAOK3—renal system—uterine cancer	0.000323	0.00318	CbGeAlD
Pazopanib—FLT4—female gonad—uterine cancer	0.000321	0.00316	CbGeAlD
Pazopanib—PDGFRA—renal system—uterine cancer	0.000321	0.00316	CbGeAlD
Pazopanib—FLT1—mammalian vulva—uterine cancer	0.000321	0.00315	CbGeAlD
Pazopanib—PIP4K2C—female gonad—uterine cancer	0.00032	0.00314	CbGeAlD
Pazopanib—PIP4K2C—vagina—uterine cancer	0.000318	0.00312	CbGeAlD
Pazopanib—FGFR1—female gonad—uterine cancer	0.000317	0.00312	CbGeAlD
Pazopanib—EPHB6—mammalian vulva—uterine cancer	0.000317	0.00312	CbGeAlD
Pazopanib—SH2B3—lymph node—uterine cancer	0.000316	0.00311	CbGeAlD
Pazopanib—FGFR1—vagina—uterine cancer	0.000315	0.0031	CbGeAlD
Pazopanib—FGF1—female reproductive system—uterine cancer	0.000314	0.00308	CbGeAlD
Pazopanib—TAOK3—endometrium—uterine cancer	0.000313	0.00307	CbGeAlD
Pazopanib—KDR—epithelium—uterine cancer	0.000313	0.00307	CbGeAlD
Pazopanib—AURKC—lymph node—uterine cancer	0.000311	0.00306	CbGeAlD
Pazopanib—KDR—uterine cervix—uterine cancer	0.00031	0.00304	CbGeAlD
Pazopanib—MAP2K5—uterine cervix—uterine cancer	0.00031	0.00304	CbGeAlD
Pazopanib—UGT1A1—renal system—uterine cancer	0.000307	0.00301	CbGeAlD
Pazopanib—FLT1—uterus—uterine cancer	0.000305	0.003	CbGeAlD
Pazopanib—STK10—mammalian vulva—uterine cancer	0.000304	0.00298	CbGeAlD
Pazopanib—MAP3K2—female gonad—uterine cancer	0.000303	0.00298	CbGeAlD
Pazopanib—TAOK3—mammalian vulva—uterine cancer	0.000302	0.00297	CbGeAlD
Pazopanib—CSF1R—uterine cervix—uterine cancer	0.000302	0.00297	CbGeAlD
Pazopanib—KDR—smooth muscle tissue—uterine cancer	0.000301	0.00296	CbGeAlD
Pazopanib—FGFR2—female reproductive system—uterine cancer	0.000296	0.00291	CbGeAlD
Pazopanib—KDR—decidua—uterine cancer	0.000295	0.0029	CbGeAlD
Pazopanib—MAP2K5—decidua—uterine cancer	0.000295	0.0029	CbGeAlD
Pazopanib—CSF1R—smooth muscle tissue—uterine cancer	0.000294	0.00289	CbGeAlD
Pazopanib—KDR—renal system—uterine cancer	0.00029	0.00285	CbGeAlD
Pazopanib—STK10—uterus—uterine cancer	0.000289	0.00284	CbGeAlD
Pazopanib—CSF1R—decidua—uterine cancer	0.000288	0.00283	CbGeAlD
Pazopanib—TAOK3—uterus—uterine cancer	0.000288	0.00283	CbGeAlD
Pazopanib—PDGFRA—uterus—uterine cancer	0.000286	0.00281	CbGeAlD
Pazopanib—FGF1—female gonad—uterine cancer	0.000285	0.00281	CbGeAlD
Pazopanib—PLK4—lymph node—uterine cancer	0.000285	0.0028	CbGeAlD
Pazopanib—LCK—female gonad—uterine cancer	0.000284	0.00279	CbGeAlD
Pazopanib—LCK—vagina—uterine cancer	0.000282	0.00277	CbGeAlD
Pazopanib—MAP2K5—endometrium—uterine cancer	0.00028	0.00275	CbGeAlD
Pazopanib—KDR—endometrium—uterine cancer	0.00028	0.00275	CbGeAlD
Pazopanib—KIT—epithelium—uterine cancer	0.000277	0.00272	CbGeAlD
Pazopanib—FLT1—female reproductive system—uterine cancer	0.000275	0.0027	CbGeAlD
Pazopanib—KIT—uterine cervix—uterine cancer	0.000275	0.0027	CbGeAlD
Pazopanib—CSF1R—endometrium—uterine cancer	0.000273	0.00269	CbGeAlD
Pazopanib—KDR—mammalian vulva—uterine cancer	0.000271	0.00266	CbGeAlD
Pazopanib—MAP2K5—mammalian vulva—uterine cancer	0.000271	0.00266	CbGeAlD
Pazopanib—PDGFRB—epithelium—uterine cancer	0.00027	0.00266	CbGeAlD
Pazopanib—FGFR2—female gonad—uterine cancer	0.00027	0.00265	CbGeAlD
Pazopanib—STK16—lymph node—uterine cancer	0.000269	0.00264	CbGeAlD
Pazopanib—PDGFRB—uterine cervix—uterine cancer	0.000268	0.00264	CbGeAlD
Pazopanib—KIT—smooth muscle tissue—uterine cancer	0.000267	0.00262	CbGeAlD
Pazopanib—RIOK2—lymph node—uterine cancer	0.000265	0.0026	CbGeAlD
Pazopanib—CSF1R—mammalian vulva—uterine cancer	0.000265	0.0026	CbGeAlD
Pazopanib—BMPR1B—lymph node—uterine cancer	0.000262	0.00258	CbGeAlD
Pazopanib—KIT—decidua—uterine cancer	0.000262	0.00257	CbGeAlD
Pazopanib—PDGFRB—smooth muscle tissue—uterine cancer	0.000261	0.00256	CbGeAlD
Pazopanib—STK10—female reproductive system—uterine cancer	0.00026	0.00255	CbGeAlD
Pazopanib—TAOK3—female reproductive system—uterine cancer	0.000259	0.00254	CbGeAlD
Pazopanib—KDR—uterus—uterine cancer	0.000258	0.00254	CbGeAlD
Pazopanib—PDGFRA—female reproductive system—uterine cancer	0.000257	0.00253	CbGeAlD
Pazopanib—KIT—renal system—uterine cancer	0.000257	0.00252	CbGeAlD
Pazopanib—PDGFRB—decidua—uterine cancer	0.000256	0.00251	CbGeAlD
Pazopanib—SLCO1B1—renal system—uterine cancer	0.000255	0.00251	CbGeAlD
Pazopanib—CSF1R—uterus—uterine cancer	0.000252	0.00248	CbGeAlD
Pazopanib—PDGFRB—renal system—uterine cancer	0.000251	0.00247	CbGeAlD
Pazopanib—FLT1—female gonad—uterine cancer	0.00025	0.00246	CbGeAlD
Pazopanib—FLT1—vagina—uterine cancer	0.000248	0.00244	CbGeAlD
Pazopanib—KIT—endometrium—uterine cancer	0.000248	0.00244	CbGeAlD
Pazopanib—EPHB6—female gonad—uterine cancer	0.000247	0.00243	CbGeAlD
Pazopanib—EPHB6—vagina—uterine cancer	0.000246	0.00241	CbGeAlD
Pazopanib—PDGFRB—endometrium—uterine cancer	0.000243	0.00238	CbGeAlD
Pazopanib—KIT—mammalian vulva—uterine cancer	0.00024	0.00236	CbGeAlD
Pazopanib—STK36—lymph node—uterine cancer	0.000238	0.00234	CbGeAlD
Pazopanib—STK10—female gonad—uterine cancer	0.000237	0.00232	CbGeAlD
Pazopanib—TAOK3—female gonad—uterine cancer	0.000236	0.00232	CbGeAlD
Pazopanib—STK10—vagina—uterine cancer	0.000235	0.00231	CbGeAlD
Pazopanib—PDGFRB—mammalian vulva—uterine cancer	0.000235	0.00231	CbGeAlD
Pazopanib—TAOK3—vagina—uterine cancer	0.000234	0.0023	CbGeAlD
Pazopanib—PI4KB—lymph node—uterine cancer	0.000234	0.0023	CbGeAlD
Pazopanib—PDGFRA—female gonad—uterine cancer	0.000234	0.0023	CbGeAlD
Pazopanib—PDGFRA—vagina—uterine cancer	0.000233	0.00229	CbGeAlD
Pazopanib—KDR—female reproductive system—uterine cancer	0.000232	0.00228	CbGeAlD
Pazopanib—MAP2K5—female reproductive system—uterine cancer	0.000232	0.00228	CbGeAlD
Pazopanib—LIMK2—lymph node—uterine cancer	0.00023	0.00226	CbGeAlD
Pazopanib—KIT—uterus—uterine cancer	0.000229	0.00225	CbGeAlD
Pazopanib—CSF1R—female reproductive system—uterine cancer	0.000227	0.00223	CbGeAlD
Pazopanib—PDGFRB—uterus—uterine cancer	0.000224	0.0022	CbGeAlD
Pazopanib—KDR—female gonad—uterine cancer	0.000211	0.00208	CbGeAlD
Pazopanib—MAP2K5—female gonad—uterine cancer	0.000211	0.00208	CbGeAlD
Pazopanib—KDR—vagina—uterine cancer	0.00021	0.00206	CbGeAlD
Pazopanib—MAP2K5—vagina—uterine cancer	0.00021	0.00206	CbGeAlD
Pazopanib—FLT4—lymph node—uterine cancer	0.000207	0.00203	CbGeAlD
Pazopanib—CSF1R—female gonad—uterine cancer	0.000206	0.00203	CbGeAlD
Pazopanib—KIT—female reproductive system—uterine cancer	0.000206	0.00202	CbGeAlD
Pazopanib—PIP4K2C—lymph node—uterine cancer	0.000205	0.00202	CbGeAlD
Pazopanib—CSF1R—vagina—uterine cancer	0.000205	0.00201	CbGeAlD
Pazopanib—SLCO1B1—female reproductive system—uterine cancer	0.000204	0.00201	CbGeAlD
Pazopanib—FGFR1—lymph node—uterine cancer	0.000204	0.002	CbGeAlD
Pazopanib—PDGFRB—female reproductive system—uterine cancer	0.000201	0.00197	CbGeAlD
Pazopanib—MAP3K2—lymph node—uterine cancer	0.000195	0.00191	CbGeAlD
Pazopanib—ABCG2—myometrium—uterine cancer	0.000194	0.0019	CbGeAlD
Pazopanib—KIT—female gonad—uterine cancer	0.000187	0.00184	CbGeAlD
Pazopanib—KIT—vagina—uterine cancer	0.000186	0.00183	CbGeAlD
Pazopanib—FGF1—lymph node—uterine cancer	0.000184	0.0018	CbGeAlD
Pazopanib—PDGFRB—female gonad—uterine cancer	0.000183	0.0018	CbGeAlD
Pazopanib—LCK—lymph node—uterine cancer	0.000182	0.00179	CbGeAlD
Pazopanib—PDGFRB—vagina—uterine cancer	0.000182	0.00179	CbGeAlD
Pazopanib—FLT1—lymph node—uterine cancer	0.000161	0.00158	CbGeAlD
Pazopanib—EPHB6—lymph node—uterine cancer	0.000159	0.00156	CbGeAlD
Pazopanib—STK10—lymph node—uterine cancer	0.000152	0.00149	CbGeAlD
Pazopanib—TAOK3—lymph node—uterine cancer	0.000151	0.00149	CbGeAlD
Pazopanib—ABCG2—uterine cervix—uterine cancer	0.000151	0.00148	CbGeAlD
Pazopanib—PDGFRA—lymph node—uterine cancer	0.000151	0.00148	CbGeAlD
Pazopanib—CYP2C8—renal system—uterine cancer	0.000145	0.00143	CbGeAlD
Pazopanib—ABCG2—decidua—uterine cancer	0.000144	0.00141	CbGeAlD
Pazopanib—CYP2C8—endometrium—uterine cancer	0.00014	0.00138	CbGeAlD
Pazopanib—ABCG2—endometrium—uterine cancer	0.000136	0.00134	CbGeAlD
Pazopanib—KDR—lymph node—uterine cancer	0.000136	0.00133	CbGeAlD
Pazopanib—MAP2K5—lymph node—uterine cancer	0.000136	0.00133	CbGeAlD
Pazopanib—CYP1A2—renal system—uterine cancer	0.000136	0.00133	CbGeAlD
Pazopanib—CSF1R—lymph node—uterine cancer	0.000133	0.0013	CbGeAlD
Pazopanib—ABCG2—mammalian vulva—uterine cancer	0.000132	0.0013	CbGeAlD
Pazopanib—ABCG2—uterus—uterine cancer	0.000126	0.00123	CbGeAlD
Pazopanib—Dizziness—Progesterone—uterine cancer	0.000121	0.00112	CcSEcCtD
Pazopanib—KIT—lymph node—uterine cancer	0.00012	0.00118	CbGeAlD
Pazopanib—Angiopathy—Etoposide—uterine cancer	0.000119	0.0011	CcSEcCtD
Pazopanib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000119	0.0011	CcSEcCtD
Pazopanib—Hepatic failure—Epirubicin—uterine cancer	0.000119	0.0011	CcSEcCtD
Pazopanib—Mediastinal disorder—Etoposide—uterine cancer	0.000119	0.0011	CcSEcCtD
Pazopanib—Chills—Etoposide—uterine cancer	0.000118	0.00109	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000118	0.00109	CcSEcCtD
Pazopanib—PDGFRB—lymph node—uterine cancer	0.000118	0.00116	CbGeAlD
Pazopanib—Cardiac failure congestive—Epirubicin—uterine cancer	0.000118	0.00109	CcSEcCtD
Pazopanib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000117	0.00108	CcSEcCtD
Pazopanib—Alopecia—Etoposide—uterine cancer	0.000116	0.00107	CcSEcCtD
Pazopanib—Vomiting—Progesterone—uterine cancer	0.000116	0.00107	CcSEcCtD
Pazopanib—CYP2C8—female reproductive system—uterine cancer	0.000116	0.00114	CbGeAlD
Pazopanib—Rash—Progesterone—uterine cancer	0.000115	0.00106	CcSEcCtD
Pazopanib—Dermatitis—Progesterone—uterine cancer	0.000115	0.00106	CcSEcCtD
Pazopanib—Headache—Progesterone—uterine cancer	0.000114	0.00106	CcSEcCtD
Pazopanib—Hot flush—Epirubicin—uterine cancer	0.000114	0.00105	CcSEcCtD
Pazopanib—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000113	0.00105	CcSEcCtD
Pazopanib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000113	0.00105	CcSEcCtD
Pazopanib—Menopausal symptoms—Epirubicin—uterine cancer	0.000113	0.00104	CcSEcCtD
Pazopanib—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000113	0.00104	CcSEcCtD
Pazopanib—Decreased appetite—Dactinomycin—uterine cancer	0.000112	0.00104	CcSEcCtD
Pazopanib—Dysgeusia—Etoposide—uterine cancer	0.000112	0.00104	CcSEcCtD
Pazopanib—Fatigue—Dactinomycin—uterine cancer	0.000111	0.00103	CcSEcCtD
Pazopanib—Pain—Dactinomycin—uterine cancer	0.00011	0.00102	CcSEcCtD
Pazopanib—Muscle spasms—Etoposide—uterine cancer	0.00011	0.00102	CcSEcCtD
Pazopanib—Hepatic failure—Doxorubicin—uterine cancer	0.00011	0.00101	CcSEcCtD
Pazopanib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000109	0.00101	CcSEcCtD
Pazopanib—Cardiac failure—Epirubicin—uterine cancer	0.000109	0.00101	CcSEcCtD
Pazopanib—Lethargy—Epirubicin—uterine cancer	0.000109	0.001	CcSEcCtD
Pazopanib—Cerebrovascular accident—Epirubicin—uterine cancer	0.000109	0.001	CcSEcCtD
Pazopanib—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000109	0.001	CcSEcCtD
Pazopanib—Nausea—Progesterone—uterine cancer	0.000109	0.001	CcSEcCtD
Pazopanib—Hyponatraemia—Epirubicin—uterine cancer	0.000107	0.000988	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000107	0.000985	CcSEcCtD
Pazopanib—Anaemia—Etoposide—uterine cancer	0.000106	0.000978	CcSEcCtD
Pazopanib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000106	0.000975	CcSEcCtD
Pazopanib—Hot flush—Doxorubicin—uterine cancer	0.000105	0.000974	CcSEcCtD
Pazopanib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000105	0.000972	CcSEcCtD
Pazopanib—CYP2C8—vagina—uterine cancer	0.000105	0.00103	CbGeAlD
Pazopanib—Menopausal symptoms—Doxorubicin—uterine cancer	0.000105	0.000965	CcSEcCtD
Pazopanib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000104	0.000964	CcSEcCtD
Pazopanib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000104	0.000963	CcSEcCtD
Pazopanib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000104	0.000958	CcSEcCtD
Pazopanib—Face oedema—Epirubicin—uterine cancer	0.000103	0.00095	CcSEcCtD
Pazopanib—ABCG2—female gonad—uterine cancer	0.000103	0.00101	CbGeAlD
Pazopanib—Leukopenia—Etoposide—uterine cancer	0.000103	0.000947	CcSEcCtD
Pazopanib—ABCG2—vagina—uterine cancer	0.000102	0.001	CbGeAlD
Pazopanib—Abdominal pain—Dactinomycin—uterine cancer	0.000102	0.000943	CcSEcCtD
Pazopanib—Cardiac failure—Doxorubicin—uterine cancer	0.000101	0.000933	CcSEcCtD
Pazopanib—Loss of consciousness—Etoposide—uterine cancer	0.000101	0.00093	CcSEcCtD
Pazopanib—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000101	0.00093	CcSEcCtD
Pazopanib—Lethargy—Doxorubicin—uterine cancer	0.000101	0.00093	CcSEcCtD
Pazopanib—Cough—Etoposide—uterine cancer	9.99e-05	0.000923	CcSEcCtD
Pazopanib—Blood creatinine increased—Epirubicin—uterine cancer	9.99e-05	0.000922	CcSEcCtD
Pazopanib—Dehydration—Epirubicin—uterine cancer	9.91e-05	0.000916	CcSEcCtD
Pazopanib—Hyponatraemia—Doxorubicin—uterine cancer	9.9e-05	0.000915	CcSEcCtD
Pazopanib—Hypertension—Etoposide—uterine cancer	9.89e-05	0.000913	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	9.86e-05	0.000911	CcSEcCtD
Pazopanib—Liver function test abnormal—Epirubicin—uterine cancer	9.84e-05	0.000909	CcSEcCtD
Pazopanib—Nausea—Medroxyprogesterone Acetate—uterine cancer	9.83e-05	0.000908	CcSEcCtD
Pazopanib—CYP3A4—renal system—uterine cancer	9.82e-05	0.000965	CbGeAlD
Pazopanib—Dry skin—Epirubicin—uterine cancer	9.77e-05	0.000902	CcSEcCtD
Pazopanib—Chest pain—Etoposide—uterine cancer	9.75e-05	0.0009	CcSEcCtD
Pazopanib—Abdominal pain upper—Epirubicin—uterine cancer	9.74e-05	0.000899	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	9.68e-05	0.000894	CcSEcCtD
Pazopanib—CYP2D6—renal system—uterine cancer	9.67e-05	0.00095	CbGeAlD
Pazopanib—Breast disorder—Epirubicin—uterine cancer	9.63e-05	0.00089	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	9.6e-05	0.000887	CcSEcCtD
Pazopanib—ABCB1—myometrium—uterine cancer	9.55e-05	0.000939	CbGeAlD
Pazopanib—Nasopharyngitis—Epirubicin—uterine cancer	9.53e-05	0.00088	CcSEcCtD
Pazopanib—Face oedema—Doxorubicin—uterine cancer	9.52e-05	0.000879	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Epirubicin—uterine cancer	9.4e-05	0.000868	CcSEcCtD
Pazopanib—Infection—Etoposide—uterine cancer	9.29e-05	0.000858	CcSEcCtD
Pazopanib—Abdominal distension—Epirubicin—uterine cancer	9.27e-05	0.000857	CcSEcCtD
Pazopanib—Asthenia—Dactinomycin—uterine cancer	9.27e-05	0.000856	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—uterine cancer	9.24e-05	0.000853	CcSEcCtD
Pazopanib—Dehydration—Doxorubicin—uterine cancer	9.17e-05	0.000847	CcSEcCtD
Pazopanib—Thrombocytopenia—Etoposide—uterine cancer	9.15e-05	0.000845	CcSEcCtD
Pazopanib—Liver function test abnormal—Doxorubicin—uterine cancer	9.11e-05	0.000841	CcSEcCtD
Pazopanib—Skin disorder—Etoposide—uterine cancer	9.08e-05	0.000838	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—uterine cancer	9.04e-05	0.000835	CcSEcCtD
Pazopanib—Hyperhidrosis—Etoposide—uterine cancer	9.04e-05	0.000835	CcSEcCtD
Pazopanib—Pancreatitis—Epirubicin—uterine cancer	9.03e-05	0.000834	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—uterine cancer	9.01e-05	0.000832	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—uterine cancer	8.91e-05	0.000823	CcSEcCtD
Pazopanib—Anorexia—Etoposide—uterine cancer	8.91e-05	0.000823	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	8.88e-05	0.00082	CcSEcCtD
Pazopanib—Diarrhoea—Dactinomycin—uterine cancer	8.84e-05	0.000816	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—uterine cancer	8.82e-05	0.000815	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	8.7e-05	0.000803	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—uterine cancer	8.61e-05	0.000796	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—uterine cancer	8.58e-05	0.000793	CcSEcCtD
Pazopanib—Photosensitivity reaction—Epirubicin—uterine cancer	8.41e-05	0.000777	CcSEcCtD
Pazopanib—Paraesthesia—Etoposide—uterine cancer	8.39e-05	0.000775	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—uterine cancer	8.36e-05	0.000772	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—uterine cancer	8.34e-05	0.00077	CcSEcCtD
Pazopanib—Dyspnoea—Etoposide—uterine cancer	8.33e-05	0.00077	CcSEcCtD
Pazopanib—Somnolence—Etoposide—uterine cancer	8.31e-05	0.000767	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—uterine cancer	8.21e-05	0.000759	CcSEcCtD
Pazopanib—Infestation—Epirubicin—uterine cancer	8.21e-05	0.000759	CcSEcCtD
Pazopanib—Vomiting—Dactinomycin—uterine cancer	8.21e-05	0.000758	CcSEcCtD
Pazopanib—Rash—Dactinomycin—uterine cancer	8.14e-05	0.000752	CcSEcCtD
Pazopanib—Decreased appetite—Etoposide—uterine cancer	8.12e-05	0.00075	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Etoposide—uterine cancer	8.07e-05	0.000745	CcSEcCtD
Pazopanib—Fatigue—Etoposide—uterine cancer	8.06e-05	0.000744	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—uterine cancer	8.01e-05	0.00074	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—uterine cancer	8.01e-05	0.00074	CcSEcCtD
Pazopanib—Pain—Etoposide—uterine cancer	7.99e-05	0.000738	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—uterine cancer	7.97e-05	0.000736	CcSEcCtD
Pazopanib—CYP3A4—female reproductive system—uterine cancer	7.87e-05	0.000773	CbGeAlD
Pazopanib—Haematuria—Epirubicin—uterine cancer	7.83e-05	0.000723	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—uterine cancer	7.78e-05	0.000719	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—uterine cancer	7.77e-05	0.000718	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—uterine cancer	7.75e-05	0.000716	CcSEcCtD
Pazopanib—CYP2D6—female reproductive system—uterine cancer	7.74e-05	0.000761	CbGeAlD
Pazopanib—Weight decreased—Doxorubicin—uterine cancer	7.71e-05	0.000712	CcSEcCtD
Pazopanib—Nausea—Dactinomycin—uterine cancer	7.67e-05	0.000708	CcSEcCtD
Pazopanib—Gastrointestinal pain—Etoposide—uterine cancer	7.64e-05	0.000706	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—uterine cancer	7.6e-05	0.000702	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—uterine cancer	7.6e-05	0.000702	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—uterine cancer	7.51e-05	0.000693	CcSEcCtD
Pazopanib—ABCB1—epithelium—uterine cancer	7.5e-05	0.000737	CbGeAlD
Pazopanib—ABCB1—uterine cervix—uterine cancer	7.43e-05	0.00073	CbGeAlD
Pazopanib—Haemoglobin—Epirubicin—uterine cancer	7.41e-05	0.000685	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—uterine cancer	7.41e-05	0.000684	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—uterine cancer	7.41e-05	0.000684	CcSEcCtD
Pazopanib—Abdominal pain—Etoposide—uterine cancer	7.39e-05	0.000682	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—uterine cancer	7.37e-05	0.000681	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—uterine cancer	7.34e-05	0.000678	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—uterine cancer	7.28e-05	0.000673	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—uterine cancer	7.26e-05	0.000671	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—uterine cancer	7.25e-05	0.000669	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—uterine cancer	7.25e-05	0.000669	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—uterine cancer	7.23e-05	0.000668	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—uterine cancer	7.19e-05	0.000664	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—uterine cancer	7.17e-05	0.000662	CcSEcCtD
Pazopanib—ABCB1—decidua—uterine cancer	7.08e-05	0.000696	CbGeAlD
Pazopanib—CYP2D6—female gonad—uterine cancer	7.04e-05	0.000692	CbGeAlD
Pazopanib—ABCB1—renal system—uterine cancer	6.95e-05	0.000683	CbGeAlD
Pazopanib—Bradycardia—Doxorubicin—uterine cancer	6.95e-05	0.000642	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—uterine cancer	6.89e-05	0.000637	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—uterine cancer	6.86e-05	0.000633	CcSEcCtD
Pazopanib—Flushing—Epirubicin—uterine cancer	6.84e-05	0.000632	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—uterine cancer	6.84e-05	0.000632	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—uterine cancer	6.82e-05	0.00063	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—uterine cancer	6.79e-05	0.000627	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—uterine cancer	6.74e-05	0.000622	CcSEcCtD
Pazopanib—ABCB1—endometrium—uterine cancer	6.72e-05	0.000661	CbGeAlD
Pazopanib—Oedema peripheral—Doxorubicin—uterine cancer	6.72e-05	0.000621	CcSEcCtD
Pazopanib—Asthenia—Etoposide—uterine cancer	6.71e-05	0.000619	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—uterine cancer	6.71e-05	0.000619	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—uterine cancer	6.69e-05	0.000618	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—uterine cancer	6.69e-05	0.000618	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—uterine cancer	6.65e-05	0.000614	CcSEcCtD
Pazopanib—Chills—Epirubicin—uterine cancer	6.62e-05	0.000611	CcSEcCtD
Pazopanib—Pruritus—Etoposide—uterine cancer	6.61e-05	0.000611	CcSEcCtD
Pazopanib—ABCG2—lymph node—uterine cancer	6.61e-05	0.000649	CbGeAlD
Pazopanib—Alopecia—Epirubicin—uterine cancer	6.52e-05	0.000602	CcSEcCtD
Pazopanib—ABCB1—mammalian vulva—uterine cancer	6.5e-05	0.000639	CbGeAlD
Pazopanib—Mental disorder—Epirubicin—uterine cancer	6.46e-05	0.000597	CcSEcCtD
Pazopanib—Erythema—Epirubicin—uterine cancer	6.42e-05	0.000593	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—uterine cancer	6.42e-05	0.000593	CcSEcCtD
Pazopanib—Diarrhoea—Etoposide—uterine cancer	6.39e-05	0.000591	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—uterine cancer	6.38e-05	0.000589	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—uterine cancer	6.33e-05	0.000585	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—uterine cancer	6.33e-05	0.000585	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—uterine cancer	6.33e-05	0.000584	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—uterine cancer	6.29e-05	0.000581	CcSEcCtD
Pazopanib—ABCB1—uterus—uterine cancer	6.2e-05	0.000609	CbGeAlD
Pazopanib—Angiopathy—Doxorubicin—uterine cancer	6.19e-05	0.000572	CcSEcCtD
Pazopanib—Dizziness—Etoposide—uterine cancer	6.18e-05	0.000571	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—uterine cancer	6.17e-05	0.00057	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—uterine cancer	6.15e-05	0.000568	CcSEcCtD
Pazopanib—Chills—Doxorubicin—uterine cancer	6.12e-05	0.000565	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—uterine cancer	6.05e-05	0.000559	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—uterine cancer	6.03e-05	0.000557	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—uterine cancer	5.98e-05	0.000552	CcSEcCtD
Pazopanib—Vomiting—Etoposide—uterine cancer	5.94e-05	0.000549	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—uterine cancer	5.94e-05	0.000549	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—uterine cancer	5.94e-05	0.000549	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—uterine cancer	5.93e-05	0.000548	CcSEcCtD
Pazopanib—Rash—Etoposide—uterine cancer	5.89e-05	0.000544	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—uterine cancer	5.89e-05	0.000544	CcSEcCtD
Pazopanib—Headache—Etoposide—uterine cancer	5.86e-05	0.000541	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—uterine cancer	5.85e-05	0.000541	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—uterine cancer	5.82e-05	0.000537	CcSEcCtD
Pazopanib—Syncope—Epirubicin—uterine cancer	5.76e-05	0.000532	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—uterine cancer	5.75e-05	0.000531	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—uterine cancer	5.71e-05	0.000527	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—uterine cancer	5.64e-05	0.000521	CcSEcCtD
Pazopanib—Cough—Epirubicin—uterine cancer	5.6e-05	0.000517	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—uterine cancer	5.6e-05	0.000517	CcSEcCtD
Pazopanib—ABCB1—female reproductive system—uterine cancer	5.57e-05	0.000547	CbGeAlD
Pazopanib—Nausea—Etoposide—uterine cancer	5.55e-05	0.000513	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—uterine cancer	5.54e-05	0.000512	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—uterine cancer	5.49e-05	0.000507	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—uterine cancer	5.47e-05	0.000505	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—uterine cancer	5.47e-05	0.000505	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—uterine cancer	5.47e-05	0.000505	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	5.43e-05	0.000501	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—uterine cancer	5.34e-05	0.000494	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—uterine cancer	5.33e-05	0.000492	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—uterine cancer	5.32e-05	0.000491	CcSEcCtD
Pazopanib—Oedema—Epirubicin—uterine cancer	5.24e-05	0.000484	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—uterine cancer	5.22e-05	0.000482	CcSEcCtD
Pazopanib—Infection—Epirubicin—uterine cancer	5.2e-05	0.000481	CcSEcCtD
Pazopanib—Cough—Doxorubicin—uterine cancer	5.18e-05	0.000479	CcSEcCtD
Pazopanib—Shock—Epirubicin—uterine cancer	5.15e-05	0.000476	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—uterine cancer	5.14e-05	0.000475	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—uterine cancer	5.13e-05	0.000474	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—uterine cancer	5.13e-05	0.000474	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—uterine cancer	5.09e-05	0.00047	CcSEcCtD
Pazopanib—ABCB1—female gonad—uterine cancer	5.07e-05	0.000498	CbGeAlD
Pazopanib—Hyperhidrosis—Epirubicin—uterine cancer	5.06e-05	0.000468	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—uterine cancer	5.06e-05	0.000467	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—uterine cancer	5.06e-05	0.000467	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—uterine cancer	5.06e-05	0.000467	CcSEcCtD
Pazopanib—ABCB1—vagina—uterine cancer	5.04e-05	0.000495	CbGeAlD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	5.02e-05	0.000464	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—uterine cancer	4.99e-05	0.000461	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—uterine cancer	4.95e-05	0.000457	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—uterine cancer	4.85e-05	0.000448	CcSEcCtD
Pazopanib—Infection—Doxorubicin—uterine cancer	4.82e-05	0.000445	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—uterine cancer	4.77e-05	0.000441	CcSEcCtD
Pazopanib—Shock—Doxorubicin—uterine cancer	4.77e-05	0.00044	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—uterine cancer	4.75e-05	0.000439	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—uterine cancer	4.75e-05	0.000438	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—uterine cancer	4.74e-05	0.000438	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—uterine cancer	4.71e-05	0.000435	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—uterine cancer	4.7e-05	0.000435	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—uterine cancer	4.69e-05	0.000433	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—uterine cancer	4.67e-05	0.000431	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—uterine cancer	4.66e-05	0.00043	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—uterine cancer	4.62e-05	0.000427	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—uterine cancer	4.61e-05	0.000426	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—uterine cancer	4.55e-05	0.000421	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—uterine cancer	4.52e-05	0.000418	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—uterine cancer	4.52e-05	0.000417	CcSEcCtD
Pazopanib—Pain—Epirubicin—uterine cancer	4.48e-05	0.000414	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	4.42e-05	0.000408	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—uterine cancer	4.38e-05	0.000405	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—uterine cancer	4.35e-05	0.000402	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—uterine cancer	4.32e-05	0.000399	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—uterine cancer	4.31e-05	0.000398	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—uterine cancer	4.28e-05	0.000396	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—uterine cancer	4.27e-05	0.000394	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—uterine cancer	4.21e-05	0.000389	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—uterine cancer	4.19e-05	0.000387	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—uterine cancer	4.18e-05	0.000386	CcSEcCtD
Pazopanib—Pain—Doxorubicin—uterine cancer	4.15e-05	0.000383	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—uterine cancer	4.14e-05	0.000383	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—uterine cancer	3.96e-05	0.000366	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—uterine cancer	3.83e-05	0.000354	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—uterine cancer	3.76e-05	0.000347	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—uterine cancer	3.71e-05	0.000342	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—uterine cancer	3.58e-05	0.000331	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—uterine cancer	3.48e-05	0.000321	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—uterine cancer	3.46e-05	0.00032	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—uterine cancer	3.43e-05	0.000317	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—uterine cancer	3.33e-05	0.000308	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—uterine cancer	3.32e-05	0.000306	CcSEcCtD
Pazopanib—Rash—Epirubicin—uterine cancer	3.3e-05	0.000305	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—uterine cancer	3.3e-05	0.000305	CcSEcCtD
Pazopanib—Headache—Epirubicin—uterine cancer	3.28e-05	0.000303	CcSEcCtD
Pazopanib—ABCB1—lymph node—uterine cancer	3.26e-05	0.00032	CbGeAlD
Pazopanib—Dizziness—Doxorubicin—uterine cancer	3.21e-05	0.000296	CcSEcCtD
Pazopanib—Nausea—Epirubicin—uterine cancer	3.11e-05	0.000287	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—uterine cancer	3.08e-05	0.000285	CcSEcCtD
Pazopanib—Rash—Doxorubicin—uterine cancer	3.06e-05	0.000282	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—uterine cancer	3.05e-05	0.000282	CcSEcCtD
Pazopanib—Headache—Doxorubicin—uterine cancer	3.04e-05	0.00028	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—uterine cancer	2.88e-05	0.000266	CcSEcCtD
Pazopanib—PDGFRB—Immune System—NRAS—uterine cancer	2.86e-06	2.28e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCL2—uterine cancer	2.85e-06	2.27e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EP300—uterine cancer	2.85e-06	2.27e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ERBB2—uterine cancer	2.85e-06	2.27e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—VEGFA—uterine cancer	2.83e-06	2.25e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—AKT1—uterine cancer	2.82e-06	2.25e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EP300—uterine cancer	2.82e-06	2.25e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—NRAS—uterine cancer	2.8e-06	2.23e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—NRAS—uterine cancer	2.79e-06	2.23e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CDKN1B—uterine cancer	2.79e-06	2.22e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—HRAS—uterine cancer	2.78e-06	2.22e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—ERBB2—uterine cancer	2.78e-06	2.22e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HRAS—uterine cancer	2.76e-06	2.2e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KRAS—uterine cancer	2.76e-06	2.2e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CXCL8—uterine cancer	2.75e-06	2.19e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KRAS—uterine cancer	2.74e-06	2.18e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—POLD1—uterine cancer	2.73e-06	2.18e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KRAS—uterine cancer	2.73e-06	2.18e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—AKT1—uterine cancer	2.71e-06	2.16e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KRAS—uterine cancer	2.71e-06	2.16e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB2—uterine cancer	2.7e-06	2.15e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP11A1—uterine cancer	2.7e-06	2.15e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CXCL8—uterine cancer	2.7e-06	2.15e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—VEGFA—uterine cancer	2.7e-06	2.15e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—PIK3CA—uterine cancer	2.7e-06	2.15e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB2—uterine cancer	2.69e-06	2.15e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CDKN1B—uterine cancer	2.68e-06	2.14e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.68e-06	2.14e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—NRAS—uterine cancer	2.66e-06	2.12e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—AKT1—uterine cancer	2.66e-06	2.12e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—KRAS—uterine cancer	2.66e-06	2.12e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ESR1—uterine cancer	2.65e-06	2.12e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—PIK3CA—uterine cancer	2.65e-06	2.11e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NRAS—uterine cancer	2.64e-06	2.1e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CDKN1B—uterine cancer	2.64e-06	2.1e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CTNNB1—uterine cancer	2.64e-06	2.1e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CDKN1B—uterine cancer	2.58e-06	2.05e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PTEN—uterine cancer	2.57e-06	2.05e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CXCL8—uterine cancer	2.56e-06	2.04e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.56e-06	2.04e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.56e-06	2.04e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CXCL8—uterine cancer	2.56e-06	2.04e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKR1C3—uterine cancer	2.55e-06	2.03e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—AKT1—uterine cancer	2.54e-06	2.03e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CTNNB1—uterine cancer	2.54e-06	2.02e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PIK3CA—uterine cancer	2.53e-06	2.02e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KRAS—uterine cancer	2.53e-06	2.01e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KRAS—uterine cancer	2.52e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—PIK3CA—uterine cancer	2.51e-06	2e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—PIK3CA—uterine cancer	2.51e-06	2e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CDKN1B—uterine cancer	2.5e-06	1.99e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CDKN1B—uterine cancer	2.5e-06	1.99e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—uterine cancer	2.49e-06	1.99e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CTNNB1—uterine cancer	2.49e-06	1.99e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PIK3CA—uterine cancer	2.49e-06	1.99e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—STK11—uterine cancer	2.49e-06	1.98e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP19A1—uterine cancer	2.49e-06	1.98e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTEN—uterine cancer	2.47e-06	1.97e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KRAS—uterine cancer	2.47e-06	1.97e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KRAS—uterine cancer	2.46e-06	1.96e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—AKT1—uterine cancer	2.46e-06	1.96e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—uterine cancer	2.45e-06	1.96e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—uterine cancer	2.45e-06	1.95e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EP300—uterine cancer	2.45e-06	1.95e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PIK3CA—uterine cancer	2.45e-06	1.95e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—AKT1—uterine cancer	2.44e-06	1.95e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CTNNB1—uterine cancer	2.43e-06	1.94e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB2—uterine cancer	2.43e-06	1.94e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTEN—uterine cancer	2.43e-06	1.94e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KRAS—uterine cancer	2.41e-06	1.92e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KRAS—uterine cancer	2.4e-06	1.92e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB2—uterine cancer	2.38e-06	1.89e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTEN—uterine cancer	2.37e-06	1.89e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CTNNB1—uterine cancer	2.36e-06	1.88e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CTNNB1—uterine cancer	2.36e-06	1.88e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EP300—uterine cancer	2.36e-06	1.88e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—STK11—uterine cancer	2.35e-06	1.87e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP19A1—uterine cancer	2.35e-06	1.87e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—uterine cancer	2.35e-06	1.87e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCL2—uterine cancer	2.34e-06	1.86e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—uterine cancer	2.33e-06	1.85e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PIK3CA—uterine cancer	2.32e-06	1.85e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—uterine cancer	2.32e-06	1.85e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EP300—uterine cancer	2.31e-06	1.85e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PIK3CA—uterine cancer	2.31e-06	1.85e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTEN—uterine cancer	2.3e-06	1.84e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—uterine cancer	2.3e-06	1.84e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	2.3e-06	1.84e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTEN—uterine cancer	2.3e-06	1.83e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—uterine cancer	2.29e-06	1.83e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—NRAS—uterine cancer	2.29e-06	1.83e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—RRM2—uterine cancer	2.28e-06	1.82e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—uterine cancer	2.27e-06	1.81e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTEN—uterine cancer	2.27e-06	1.81e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	2.27e-06	1.81e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—uterine cancer	2.26e-06	1.8e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EP300—uterine cancer	2.26e-06	1.8e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PIK3CA—uterine cancer	2.26e-06	1.8e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CXCL8—uterine cancer	2.25e-06	1.8e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	2.25e-06	1.79e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—uterine cancer	2.23e-06	1.78e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—DCN—uterine cancer	2.21e-06	1.76e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—PIK3CA—uterine cancer	2.21e-06	1.76e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PIK3CA—uterine cancer	2.21e-06	1.76e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NRAS—uterine cancer	2.2e-06	1.76e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—AKT1—uterine cancer	2.2e-06	1.76e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1B—uterine cancer	2.2e-06	1.75e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EP300—uterine cancer	2.2e-06	1.75e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—uterine cancer	2.19e-06	1.75e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—uterine cancer	2.19e-06	1.75e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EP300—uterine cancer	2.19e-06	1.75e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—uterine cancer	2.17e-06	1.73e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—uterine cancer	2.16e-06	1.72e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—EP300—uterine cancer	2.16e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—uterine cancer	2.15e-06	1.71e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—uterine cancer	2.15e-06	1.71e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—uterine cancer	2.14e-06	1.71e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—uterine cancer	2.14e-06	1.7e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	2.12e-06	1.69e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—uterine cancer	2.12e-06	1.69e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—uterine cancer	2.11e-06	1.68e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	2.1e-06	1.67e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—uterine cancer	2.09e-06	1.67e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—uterine cancer	2.09e-06	1.66e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.08e-06	1.66e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—uterine cancer	2.08e-06	1.66e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—uterine cancer	2.08e-06	1.66e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—uterine cancer	2.08e-06	1.66e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—uterine cancer	2.08e-06	1.65e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—uterine cancer	2.07e-06	1.65e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	2.07e-06	1.65e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—uterine cancer	2.06e-06	1.64e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—uterine cancer	2.05e-06	1.64e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—uterine cancer	2.05e-06	1.63e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—uterine cancer	2.05e-06	1.63e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—uterine cancer	2.05e-06	1.63e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—uterine cancer	2.04e-06	1.63e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—uterine cancer	2.04e-06	1.62e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—uterine cancer	2.03e-06	1.62e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—uterine cancer	2.03e-06	1.62e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—uterine cancer	2e-06	1.59e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP19A1—uterine cancer	1.99e-06	1.58e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—STK11—uterine cancer	1.99e-06	1.58e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—EP300—uterine cancer	1.98e-06	1.58e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EP300—uterine cancer	1.97e-06	1.57e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—uterine cancer	1.97e-06	1.57e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.97e-06	1.57e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—uterine cancer	1.95e-06	1.55e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—uterine cancer	1.95e-06	1.55e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EP300—uterine cancer	1.93e-06	1.54e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—uterine cancer	1.93e-06	1.54e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—uterine cancer	1.92e-06	1.53e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—uterine cancer	1.9e-06	1.51e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—uterine cancer	1.9e-06	1.51e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.89e-06	1.51e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—uterine cancer	1.89e-06	1.51e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—uterine cancer	1.87e-06	1.49e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	1.87e-06	1.49e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.87e-06	1.49e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—uterine cancer	1.86e-06	1.49e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	1.85e-06	1.48e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCL8—uterine cancer	1.85e-06	1.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	1.85e-06	1.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—uterine cancer	1.85e-06	1.47e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—EP300—uterine cancer	1.84e-06	1.46e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—uterine cancer	1.83e-06	1.46e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—uterine cancer	1.82e-06	1.45e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—uterine cancer	1.81e-06	1.45e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—uterine cancer	1.81e-06	1.44e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—uterine cancer	1.81e-06	1.44e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—uterine cancer	1.8e-06	1.44e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1B—uterine cancer	1.8e-06	1.44e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.78e-06	1.42e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—uterine cancer	1.77e-06	1.41e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—uterine cancer	1.76e-06	1.41e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—uterine cancer	1.76e-06	1.41e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—uterine cancer	1.74e-06	1.39e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—uterine cancer	1.72e-06	1.37e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—uterine cancer	1.71e-06	1.37e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—uterine cancer	1.7e-06	1.36e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—uterine cancer	1.7e-06	1.36e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—uterine cancer	1.69e-06	1.34e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—uterine cancer	1.68e-06	1.34e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—uterine cancer	1.67e-06	1.33e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—uterine cancer	1.66e-06	1.32e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—uterine cancer	1.66e-06	1.32e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—uterine cancer	1.63e-06	1.3e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—uterine cancer	1.62e-06	1.29e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—uterine cancer	1.61e-06	1.29e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—uterine cancer	1.6e-06	1.28e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	1.59e-06	1.27e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—uterine cancer	1.58e-06	1.26e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EP300—uterine cancer	1.58e-06	1.26e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—uterine cancer	1.57e-06	1.25e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—uterine cancer	1.57e-06	1.25e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—uterine cancer	1.56e-06	1.24e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—uterine cancer	1.55e-06	1.23e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—STK11—uterine cancer	1.53e-06	1.22e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.53e-06	1.22e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—uterine cancer	1.5e-06	1.2e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—uterine cancer	1.5e-06	1.2e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—uterine cancer	1.5e-06	1.2e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—uterine cancer	1.49e-06	1.19e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—uterine cancer	1.48e-06	1.18e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—uterine cancer	1.48e-06	1.18e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—uterine cancer	1.47e-06	1.17e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	1.46e-06	1.16e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—uterine cancer	1.43e-06	1.14e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—uterine cancer	1.42e-06	1.14e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—uterine cancer	1.41e-06	1.13e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—uterine cancer	1.4e-06	1.12e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—uterine cancer	1.38e-06	1.1e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—uterine cancer	1.37e-06	1.09e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—uterine cancer	1.36e-06	1.08e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	1.35e-06	1.08e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—uterine cancer	1.33e-06	1.06e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—uterine cancer	1.32e-06	1.06e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—uterine cancer	1.32e-06	1.05e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.32e-06	1.05e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—uterine cancer	1.31e-06	1.04e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—uterine cancer	1.28e-06	1.02e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—uterine cancer	1.2e-06	9.55e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—uterine cancer	1.19e-06	9.52e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	1.19e-06	9.51e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—uterine cancer	1.17e-06	9.34e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—uterine cancer	1.17e-06	9.31e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—uterine cancer	1.15e-06	9.19e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—EP300—uterine cancer	1.14e-06	9.08e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—uterine cancer	1.13e-06	9.04e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—uterine cancer	1.11e-06	8.84e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—uterine cancer	1.08e-06	8.64e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—uterine cancer	1.04e-06	8.3e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—EP300—uterine cancer	9.92e-07	7.91e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—uterine cancer	9.8e-07	7.82e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—uterine cancer	9.57e-07	7.63e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—EP300—uterine cancer	9.35e-07	7.46e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—uterine cancer	8.43e-07	6.72e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—uterine cancer	8.31e-07	6.62e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—EP300—uterine cancer	7.92e-07	6.32e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—uterine cancer	7.34e-07	5.85e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—uterine cancer	6.92e-07	5.51e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—uterine cancer	6.88e-07	5.49e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—uterine cancer	6.41e-07	5.11e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—EP300—uterine cancer	6.11e-07	4.87e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—uterine cancer	6e-07	4.78e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—uterine cancer	5.86e-07	4.67e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—uterine cancer	5.65e-07	4.51e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—uterine cancer	4.79e-07	3.82e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—uterine cancer	4.52e-07	3.61e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—uterine cancer	3.69e-07	2.95e-06	CbGpPWpGaD
